Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm study of JCAR015 in adult B-cell acute lymphoblastic leukemia
2016-001706-42Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Aug 2016
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Vadacabtagene leraleucel in acute lymphoblastic leukemia (ALL), sponsored by Celgene Corporation. Primary endpoint: Primary - safety and feasibility (Cohorts 1–4). Started Aug 2016; status: terminated.
02
Drugs
Vadacabtagene leraleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2016-001706-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001706-42.